Aston Particle Technologies Limited

The annual economic burden of asthma and chronic obstructive pulmonary disease (COPD) on the NHS in the UK is in the order of £4.9 billion. A National Institute of Health and Care Excellence (NICE) statement suggests that two thirds of asthma deaths would be preventable with better access to basic care and the right treatment. Latest guidelines for treatm...

no public description

Experimental development of Continuous manufacturing technology

At the present time there are few, if any, manufacturing processes for particle surface modification that do not adversely affect the innate properties of the core particles. State-of-the-art blending technologies for DPIs, e.g. high shear or turbula mixing, often are unsuitable for processing poorly stable APIs and even when suitable, create highly varia...

The global market for treatment of asthma and COPD is estimated to be $41.7B in 2017. Dry powder inhalers (DPI) make up nearly 50% of the market by sales value (FDA, 2015). The formulation and performance of a DPI is affected by complex interactions between drug substance, excipients and inhalation device. Current technologies for developing DPIs, such as...

There is a lack of available technologies for particle surface modification that do not affect the particles physical and chemical properties. Currently 70% of new drugs being developed exhibit poor solubility and this provides a huge challenge and high cost for drug development in the pharmaceutical market. Current techniques are expensive, produce low y...

Aston Particle Technologies offers a one-step particle engineering technology that processes drug without the use of solvents and heat. Its USP lies in delivering enhanced particle properties for challenging drugs (high dose, moisture sensitive or heat sensitive) at low cost.